Altimmune Inc.
http://altimmune.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Altimmune Inc.
A Look Into The Future Of NASH
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.
Obesity Market Potential Is Huge, But Access To Drugs An Increasing Challenge
Despite double-digit weight loss across several drugs presented at ADA, experts note access to obesity therapies will be constrained without outcomes data to justify their widespread use and cost.
Lilly Looks To Complement Mounjaro, Obesity Pipeline With Versanis Buyout
Deal brings Lilly a Phase II activin receptor-targeting antibody that could provide another tool in battling obesity. This is Lilly’s fourth M&A transaction since 20 June.
Merck And Altimmune Vie To Be Leaders In NAFLD And NASH
While progress in NASH has been slow for years, two dual GLP-1/GR agonists from rivals Merck & Co and Altimmune are showing mid-stage promise.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- Immune Targeting Systems (ITS) Ltd.
- ImmuneFocus Corporation
- PharmAthene Inc.
- Spitfire Pharma, Inc.
- Vaxin Pharmaceuticals
- Vaxin Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice